Loading…
Cadrenal Therapeutics, Inc. is projected to decline to $1.63 by 2027, a -17% move from its current price of $1.96. CVKD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.87 | $1.96 | $2.05 | +0.03% |
| Aug 6 | $1.84 | $1.96 | $2.09 | +0.05% |
| Aug 7 | $1.81 | $1.96 | $2.12 | +0.08% |
| Aug 8 | $1.79 | $1.96 | $2.15 | +0.10% |
| Aug 9 | $1.77 | $1.96 | $2.17 | +0.13% |
| Aug 10 | $1.75 | $1.96 | $2.20 | +0.16% |
| Aug 11 | $1.74 | $1.96 | $2.22 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.74 | $1.96 | $2.22 | +0.18% |
| Week 2 | $1.66 | $1.97 | $2.34 | +0.37% |
| Week 3 | $1.60 | $1.97 | $2.43 | +0.55% |
| Week 4 | $1.55 | $1.97 | $2.52 | +0.74% |
| Week 5 | $1.51 | $1.98 | $2.59 | +0.92% |
| Week 6 | $1.47 | $1.98 | $2.67 | +1.11% |
| Week 7 | $1.44 | $1.99 | $2.74 | +1.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation.
It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company’s other programs include CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, which has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. Cadrenal was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc. (CVKD) currently trades at $1.97 per share and has a market capitalization of $6.1M, ranking 5222. The stock sits amid a complex near-term setup, with a forecast that shows a range of potential outcomes over the coming years.
In the near term, the trajectory is expected to be flat to modestly moving within a broader long-term context of upside potential. The long-range outlook signals meaningful upside in the later years, with the maximums reaching multiple dollars above today’s price in the 2040–2050 horizon.
A major floor 54.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.5% away) — a key level to hold.
The nearest ceiling, 83.7% above — a clean break opens room to run.
A major ceiling 240.3% above — clearing it would confirm fresh momentum.
Key CVKD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CVKD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.03 | Sell | $2.04 | Sell |
| MA 10 | $2.06 | Sell | $2.12 | Sell |
| MA 20 | $2.39 | Sell | $2.38 | Sell |
| MA 50 | $3.33 | Sell | $3.23 | Sell |
| MA 100 | $4.52 | Sell | $4.44 | Sell |
| MA 200 | $6.87 | Sell | $6.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.74 | Neutral |
| Stoch RSI (14) | 71.79 | Neutral |
| CCI (20) | -69.31 | Neutral |
| Williams %R (14) | -91.11 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -14.47 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 8.89 | Buy |
| TRIX (15) | -2.00 | Sell |
| Awesome (5,34) | -0.70 | Sell |
| Ultimate (7,14,28) | 34.29 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 2.01 | Sell |
| ADX (14) | 37.02 | Sell |
| ATR (14) | 0.12 | Info |
The 30-day technical picture is Neutral, with the RSI14 at 30. The stock’s near-term trend is tempered by this neutral momentum. The 50-day simple moving average is $3.45 and the 200-day simple moving average is $6.99, indicating a longer-term defensive posture relative to recent price action.
Support sits at $1.97 and resistance at $3.60, framing a 30-day price range from $1.45 to $2.67.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.96 | $1.96 | $2.37 | 0% | Neutral | |
| $1.22 | $1.63 | $2.34 | -17% | Bearish | |
| $1.14 | $1.60 | $2.44 | -18% | Bearish | |
| $1.37 | $2.01 | $3.21 | +3% | Neutral | |
| $1.49 | $2.28 | $3.76 | +16% | Neutral | |
| $1.48 | $2.34 | $3.99 | +19% | Neutral | |
| $1.37 | $2.25 | $3.94 | +15% | Neutral | |
| $1.25 | $2.11 | $3.78 | +8% | Neutral | |
| $1.24 | $2.16 | $3.97 | +10% | Neutral | |
| $1.13 | $2.04 | $3.83 | +4% | Neutral | |
| $1.42 | $2.94 | $6.03 | +50% | Bullish | |
| $2.72 | $6.05 | $13.92 | +209% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.96 | $1.96 | $2.34 | +0.00% |
| September 2026 | $1.59 | $1.92 | $2.40 | -2.22% |
| October 2026 | $1.65 | $2.01 | $2.56 | +4.74% |
| November 2026 | $1.59 | $1.96 | $2.54 | -2.27% |
| December 2026 | $1.46 | $1.81 | $2.37 | -7.60% |
Click any year to see its month-by-month CVKD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CVKD to range from $1.96 to $2.37 through 2026. The $1.96 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The CVKD price prediction for 2027 points to an average of $1.63 (low $1.22, high $2.34) — a potential decline of -17% on today's $1.96. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2028, CVKD is projected to trade between $1.14 and $2.44, averaging $1.60 — a potential decline of -18% from today's $1.96. That is -2% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
Cadrenal Therapeutics, Inc.'s 2029 outlook centres on $2.01, within a $1.37 to $3.21 range. That is up +26% on the projected 2028 average. That marks a +3% change versus current levels. Price action looks broadly range-bound.
By 2030, CVKD could reach as high as $3.76, with a base case around $2.28 and support toward $1.49 — roughly +16% from $1.96. A consolidation phase looks the most probable path here.
Expect CVKD to range from $1.48 to $3.99 through 2031. The $2.34 average target implies a +19% move from current prices. That is up +3% on the projected 2030 average. Price action looks broadly range-bound.
The CVKD price prediction for 2032 points to an average of $2.25 (low $1.37, high $3.94) — a potential gain of +15% on today's $1.96. A consolidation phase looks the most probable path here.
In 2033, CVKD is projected to trade between $1.25 and $3.78, averaging $2.11 — a potential gain of +8% from today's $1.96. That is -6% versus the projected 2032 average. Price action looks broadly range-bound.
Cadrenal Therapeutics, Inc.'s 2034 outlook centres on $2.16, within a $1.24 to $3.97 range. That is up +3% on the projected 2033 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, CVKD could reach as high as $3.83, with a base case around $2.04 and support toward $1.13 — roughly +4% from $1.96. Price action looks broadly range-bound.
Expect CVKD to range from $1.42 to $6.03 through 2040. The $2.94 average target implies a +50% move from current prices. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The CVKD price prediction for 2050 points to an average of $6.05 (low $2.72, high $13.92) — a potential gain of +209% on today's $1.96. Momentum favours further upside here.
Investing $1,000 in CVKD today (≈ 510.204082 CVKD) could be worth
$3,088.62
+$2,088.62 (+209%) by 2050 · US Dollar
Based on the average projected CVKD price of $6.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CVKDwould be worth at today's price.
$1,000 invested in CVKD on Jul 31, 2025 (≈ 95.969289 CVKD) would be worth
$188.1
-$811.9 (-81.2%) today · 0.19× · US Dollar
Based on a CVKD entry price of $10.42 vs. today's $1.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.04 | $960.78 | -3.9% |
| 1 month ago | $3.17 | $618.3 | -38.2% |
| 3 months ago | $6.35 | $308.66 | -69.1% |
| 6 months ago | $6.68 | $293.41 | -70.7% |
| 1 year ago | $10.42 | $188.1 | -81.2% |
| All time (3.5y) ago | $61.8 | $31.72 | -96.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CVKD forecast.
Our base-case forecast reaches $3.90 around 2050.
Implied market cap at $3.90: $12.08M
The multi-year forecast shows a mix of near-term pressure and longer-term upside. In 2026 the min and average are both $1.97 with a max of $2.37, yielding 0% ROI and a Neutral sentiment. The 2027 and 2028 forecasts are Bearish, with 2027 averaging $1.65 (min $1.23, max $2.38) for a -16.2% ROI and 2028 averaging $1.60 (min $1.13, max $2.44) for a -19% ROI.
In 2029 the average rises to $2.03 (min $1.38, max $3.24) with a 2.9% ROI, followed by 2030 at an average of $2.31 (min $1.51, max $3.83) for a 17.3% ROI, and 2031 at an average of $2.33 (min $1.47, max $3.99) for an 18.4% ROI. The trajectory remains Neutral through 2032–2035, with 2032 averaging $2.27 and 2033 averaging $2.13, both carrying mid-to-high single-digit ROI figures. By 2040, the forecast turns bullish: average $2.94 with a max of $6.05 and a 49.4% ROI.
In 2050, the forecast is bullish again, with an average of $6.07 and a max of $13.97, delivering a 208.2% ROI. These figures reflect a broad long-term upside despite intermediate periods of softer performance.
Tap a question to reveal the answer.
Avg $2.31 with a max of $3.83 and a min of $1.51; ROI 17.3%; sentiment Neutral.
The forecast shows mixed guidance: Neutral in 2026 and across several mid-term years, with Bearish readings in 2027 and 2028, followed by Neutral to bullish readings in the later years, including 2040 (Bullish) and 2050 (Bullish). The long-run upside is indicated by a 2050 max of $13.97 and a 208.2% ROI, but there are multiple years with negative or modest returns along the way.
Yes, the 2050 forecast shows a max of $13.97, which exceeds $10, corresponding to a 208.2% ROI in that year.
Current price is $1.97 and market capitalization is $6.1M.
Low $1.45 and high $2.67.
Cadrenal Therapeutics, Inc. Community Discussion
0Share your Cadrenal Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.